Sign In
Buy VIR
Vir Biotechnology Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | -$0.700 |
| EPS actual | -$1.17 |
| EPS Surprise | -67.14% |
| Revenue estimate | 1.555M |
| Revenue actual | 240K |
| Revenue Surprise | -84.57% |
| Release date | Aug 06, 2025 |
| EPS estimate | -$0.720 |
| EPS actual | -$0.80 |
| EPS Surprise | -11.11% |
| Revenue estimate | 2.722M |
| Revenue actual | 1.214M |
| Revenue Surprise | -55.40% |
| Release date | May 07, 2025 |
| EPS estimate | -$0.83 |
| EPS actual | -$0.88 |
| EPS Surprise | -6.02% |
| Revenue estimate | 8.592M |
| Revenue actual | 1.794M |
| Revenue Surprise | -79.12% |
| Release date | Feb 26, 2025 |
| EPS estimate | -$0.85 |
| EPS actual | -$0.760 |
| EPS Surprise | 10.59% |
| Revenue estimate | 8.14M |
| Revenue actual | 12.374M |
| Revenue Surprise | 52.01% |
Last 4 Quarters for Vir Biotechnology
Below you can see how VIR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 26, 2025 |
| Price on release | $9.20 |
| EPS estimate | -$0.85 |
| EPS actual | -$0.760 |
| EPS surprise | 10.59% |
| Date | Price |
|---|---|
| Feb 20, 2025 | $9.80 |
| Feb 21, 2025 | $9.57 |
| Feb 24, 2025 | $9.47 |
| Feb 25, 2025 | $9.10 |
| Feb 26, 2025 | $9.20 |
| Feb 27, 2025 | $8.11 |
| Feb 28, 2025 | $8.39 |
| Mar 03, 2025 | $7.92 |
| Mar 04, 2025 | $8.20 |
| 4 days before | -6.12% |
| 4 days after | -10.87% |
| On release day | -11.85% |
| Change in period | -16.33% |
| Release date | May 07, 2025 |
| Price on release | $5.61 |
| EPS estimate | -$0.83 |
| EPS actual | -$0.88 |
| EPS surprise | -6.02% |
| Date | Price |
|---|---|
| May 01, 2025 | $6.08 |
| May 02, 2025 | $6.16 |
| May 05, 2025 | $6.15 |
| May 06, 2025 | $5.63 |
| May 07, 2025 | $5.61 |
| May 08, 2025 | $5.41 |
| May 09, 2025 | $5.09 |
| May 12, 2025 | $5.30 |
| May 13, 2025 | $4.70 |
| 4 days before | -7.73% |
| 4 days after | -16.22% |
| On release day | -3.57% |
| Change in period | -22.70% |
| Release date | Aug 06, 2025 |
| Price on release | $5.08 |
| EPS estimate | -$0.720 |
| EPS actual | -$0.80 |
| EPS surprise | -11.11% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $5.07 |
| Aug 01, 2025 | $5.03 |
| Aug 04, 2025 | $5.10 |
| Aug 05, 2025 | $5.11 |
| Aug 06, 2025 | $5.08 |
| Aug 07, 2025 | $4.35 |
| Aug 08, 2025 | $4.30 |
| Aug 11, 2025 | $4.28 |
| Aug 12, 2025 | $4.36 |
| 4 days before | 0.197% |
| 4 days after | -14.17% |
| On release day | -14.37% |
| Change in period | -14.00% |
| Release date | Nov 05, 2025 |
| Price on release | $5.40 |
| EPS estimate | -$0.700 |
| EPS actual | -$1.17 |
| EPS surprise | -67.14% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $5.93 |
| Oct 31, 2025 | $5.96 |
| Nov 03, 2025 | $5.60 |
| Nov 04, 2025 | $5.25 |
| Nov 05, 2025 | $5.40 |
| Nov 06, 2025 | $5.12 |
| Nov 07, 2025 | $5.13 |
| Nov 10, 2025 | $5.37 |
| Nov 11, 2025 | $5.71 |
| 4 days before | -8.94% |
| 4 days after | 5.74% |
| On release day | -5.19% |
| Change in period | -3.71% |
Vir Biotechnology Earnings Call Transcript Summary of Q3 2025
Vir Biotechnology reported multiple operational and clinical milestones in Q3 2025 that position the company for several near-term value catalysts. Key clinical achievements include completion of enrollment in ECLIPSE 1 (registrational Phase III for hepatitis delta) ahead of schedule, continued strong enrollment in ECLIPSE 2 and ECLIPSE 3, and an upcoming presentation of the complete 48-week SOLSTICE data at AASLD on November 9. The company guided to primary completion of ECLIPSE 1 in Q4 2026 and top-line data for all three ECLIPSE studies by Q1 2027. In oncology, Vir plans a comprehensive data update for VIR-5500 (PRO-XTEN masked PSMA-targeted T-cell engager) in Q1 2026 and continues dose escalation across weekly and every-3-week schedules; first patient has been dosed in a first-line mCRPC combination study. Other T-cell engager programs (VIR-5818 HER2 and VIR-5525 EGFR) are progressing in dose escalation and Phase I enrollment. Financially, Q3 R&D and SG&A expenses declined year-over-year driven by lower license expense and restructuring savings; net loss narrowed to $163.1M for the quarter. Cash, cash equivalents and investments totaled approximately $810.7M at quarter end, with a projected runway into mid-2027 under current plans. Capital deployment remains prioritized to the hepatitis delta registrational program and the VIR-5500 oncology program, while advancing other TCE programs and preclinical candidates and pursuing business development opportunities.
